AVITA Medical, Inc. (RCEL)
NASDAQ: RCEL · Real-Time Price · USD
3.930
-0.150 (-3.68%)
Feb 5, 2026, 4:00 PM EST - Market closed
AVITA Medical Stock Forecast
Stock Price Forecast
The 3 analysts that cover AVITA Medical stock have a consensus rating of "Buy" and an average price target of $7.17, which forecasts a 82.44% increase in the stock price over the next year. The lowest target is $3.50 and the highest is $10.
Price Target: $7.17 (+82.44%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for AVITA Medical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 1 | 1 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +154.45% | Jan 26, 2026 |
| Lake Street | Lake Street | Hold Maintains $3 → $3.5 | Hold | Maintains | $3 → $3.5 | -10.94% | Jan 16, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 → $10 | Strong Buy | Maintains | $14 → $10 | +154.45% | Jan 15, 2026 |
| BTIG | BTIG | Strong Sell → Hold Upgrades n/a | Strong Sell → Hold | Upgrades | n/a | n/a | Nov 20, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +256.23% | Nov 7, 2025 |
Financial Forecast
Revenue This Year
73.00M
from 64.25M
Increased by 13.61%
Revenue Next Year
87.31M
from 73.00M
Increased by 19.61%
EPS This Year
-1.53
from -2.39
EPS Next Year
-0.88
from -1.53
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 76.4M | 105.3M | ||||
| Avg | 73.0M | 87.3M | ||||
| Low | 68.8M | 78.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 19.0% | 44.3% | ||||
| Avg | 13.6% | 19.6% | ||||
| Low | 7.1% | 7.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.38 | -0.18 | ||||
| Avg | -1.53 | -0.88 | ||||
| Low | -1.86 | -1.50 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.